The first pilot of rapid assessment of WP5 JA2 Strand A on ‘Zostavax for the prevention herpes zoster’ is now available

We are pleased to announce the publication of the first pilot rapid assessment of WP5 JA2 Strand A.

This pilot rapid assessment evaluates the herpes zoster vaccine ‘Zostavax’ and its prevention of herpes zoster and post herpetic neuralgia.’

Please find the report including appendices here.

In case of any questions, please contact Lidia Becla (lbecla@cvz.nl).